Related Experiment Video
Updated: Dec 8, 2025

Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation
Published on: July 20, 2022
Evaluating Serum Heat Shock Protein Levels as Novel Biomarkers for Atrial Fibrillation
Denise M S van Marion1, Eva A H Lanters2, Kennedy S Ramos1,2
1Department of Physiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, Vrije University, 1081HV Amsterdam, The Netherlands.
Insights
Heat shock proteins (HSP) do not stage atrial fibrillation (AF) or predict recurrence. However, elevated HSP27 levels after pulmonary vein isolation (PVI) may indicate future AF recurrence in patients.
Area of Science:
- Cardiology
- Biomarkers
- Electrophysiology
Background:
- Atrial fibrillation (AF) staging is crucial for understanding disease progression and treatment outcomes.
- Blood-based heat shock protein (HSP) levels are investigated as potential biomarkers for AF staging and predicting recurrence.
- Identifying patients at higher risk for AF recurrence post-treatment is essential.
Purpose of the Study:
- To evaluate the relationship between serum HSP levels and the presence/stage of AF.
- To assess the correlation between serum HSP levels and AF recurrence after electrocardioversion (ECV) or pulmonary vein isolation (PVI).
- To determine if HSP levels can predict AF recurrence post-ablation.
Main Methods:
- Serum samples were collected from 297 participants (98 controls, 199 AF patients) undergoing ECV or PVI.
- Levels of HSP27, HSP70, cardiovascular (cv)HSP, and HSP60 were measured pre-intervention and at 3, 6, and 12 months post-PVI.
- Statistical analyses were performed to compare HSP levels across AF stages and correlate them with recurrence.
Main Results:
- No significant differences in baseline HSP levels were found between control and AF patients across different stages (PAF, PeAF, LSPeAF).
- Baseline HSP levels did not correlate with AF recurrence following ECV or PVI.
- In patients experiencing AF recurrence post-PVI, HSP27 levels were significantly elevated compared to baseline, unlike in non-recurrent cases.
Conclusions:
- Baseline serum HSP levels do not appear to be associated with AF presence, stage, or recurrence risk.
- Elevated HSP27 levels post-PVI may serve as a predictive marker for AF recurrence within one year of ablative therapy.
- Further research into HSP27's role in post-ablation AF recurrence is warranted.
Abstract:
Background: Staging of atrial fibrillation (AF) is essential to understanding disease progression and the accompanied increase in therapy failure. Blood-based heat shock protein (HSP) levels may enable staging of AF and the identification of patients with higher risk for AF recurrence after treatment. Objective: This study evaluates the relationship between serum HSP levels, presence of AF, AF stage and AF recurrence following electrocardioversion (ECV) or pulmonary vein isolation (PVI). Methods: To determine HSP27, HSP70, cardiovascular (cv)HSP and HSP60 levels, serum samples were collected from control patients without AF and patients with paroxysmal atrial fibrillation (PAF), persistent (PeAF) and longstanding persistent (LSPeAF) AF, presenting for ECV or PVI, prior to intervention and at 3-, 6- and 12-months post-PVI. Results: The study population (n = 297) consisted of 98 control and 199 AF patients admitted for ECV (n = 98) or PVI (n = 101). HSP27, HSP70, cvHSP and HSP60 serum levels did not differ between patients without or with PAF, PeAF or LSPeAF. Additionally, baseline HSP levels did not correlate with AF recurrence after ECV or PVI. However, in AF patients with AF recurrence, HSP27 levels were significantly elevated post-PVI relative to baseline, compared to patients without recurrence. Conclusions: No association was observed between baseline HSP levels and the presence of AF, AF stage or AF recurrence. However, HSP27 levels were increased in serum samples of patients with AF recurrence within one year after PVI, suggesting that HSP27 levels may predict recurrence of AF after ablative therapy.
Related Concept Videos
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Dysrhythmias V: Evaluating Dysrhythmias
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Acute Coronary Syndrome III: Diagnostic Studies

